Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Cash & Current Investments came in at $3.3 billion in Q2 2026, up 15.77% YoY from $2.9 billion in Q2 2025, and up 9.93% on a QoQ basis from $3.0 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Cash & Current Investments data on file, last reported at $3.3 billion in Q2 2026.
- Quarterly Cash & Current Investments rose 15.77% year-over-year to $3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (up 15.77% YoY) and the FY2025 annual result came in at $2.9 billion, up 8.18% from the prior year.
- Cash & Current Investments advanced to $3.3 billion in Q2 2026, from $3.0 billion in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $3.3 billion in Q2 2026 to a low of $2.0 billion in Q2 2023.
- A 5-year average of $2.5 billion and a median of $2.5 billion in 2023 frame the typical range for Cash & Current Investments.
- The widest YoY moves for Cash & Current Investments: up 33.58% in 2022, down 8.62% in 2022.
- Tracing ALNY's Cash & Current Investments over 5 years: stood at $2.2 billion in 2022, then rose by 12.08% to $2.4 billion in 2023, then grew by 10.72% to $2.7 billion in 2024, then increased by 8.18% to $2.9 billion in 2025, then grew by 13.74% to $3.3 billion in 2026.
- The last three Cash & Current Investments figures came in at $3.3 billion (Q2 2026), $3.0 billion (Q1 2026), and $2.9 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.31 Bn |
| Mar 31, 2026 | 3.01 Bn |
| Dec 31, 2025 | 2.91 Bn |
| Sep 30, 2025 | 1.49 Bn |
| Jun 30, 2025 | 1.11 Bn |
| Mar 31, 2025 | 2.63 Bn |
| Dec 31, 2024 | 976.81 Mn |
| Sep 30, 2024 | 1.11 Bn |
| Jun 30, 2024 | 2.61 Bn |
| Mar 31, 2024 | 693.14 Mn |
| Dec 31, 2023 | 2.43 Bn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 685.06 Mn |
| Mar 31, 2023 | 698.10 Mn |
| Dec 31, 2022 | 2.17 Bn |
| Sep 30, 2022 | 1.10 Bn |
| Jun 30, 2022 | 606.46 Mn |
| Mar 31, 2022 | 2.21 Bn |
| Dec 31, 2021 | 889.13 Mn |
| Sep 30, 2021 | 1.17 Bn |